FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2394497789> ?p ?o ?g. }

• W2394497789 endingPage "312" @default.
• W2394497789 startingPage "304" @default.
• W2394497789 abstract "Human blood monocytes (Mo) and monocyte-derived macrophages (MØ) are known to be potent antitumor cytotoxic effector cells through activation with recombinant human interferon gamma (rIFN-y), bacterial muramyldipeptide or the synthetic derivative muramyltripeptide phosphatidylethanolamine entrapped in liposomes (L-MTP-PE). Large-scale generation of ex vivo activated Mo from the blood of cancer patients proved feasible. We report our experience with a fixed rotor speed counterflow centrifugation elutration (CEE) procedure using the newly available Beckman high capacity JE-5.0 rotor system that reproducibly isolates up to 1.0-1.5×10 9 Mo with > 90% purity, in suspension and functionally intact derived from peripheral blood mononuclear cell-enriched suspensions obtained by leukapheresis (LP) from healthy volunteers and cancer patients. The semiclosed, easy to handle CCE system, was adapted to a sterile technique that permitted clinical trials in adoptive monocyte immunotherapy. Freshly isolated Mo did not lose morphological or functional integrity and had no spontaneous activation. Their abilities to become activated to the cytotoxic state after 18-h stimulation with 500 U/ml rIFN-γ or 1 μg/ml L-MTP-PE and to differentiate into matured MØ in vitro were not altered. The system was therefore used to isolate large numbers of Mo for a phase I clinical trial of intraperitoneal immunotherapy with L-MTP-PE activated autologous Mo in nine patients with peritoneal carcinomatosis. Each patient received weekly Mo infusions (n=5) with an intrapatient dose escalation schedule (from 10 7 to 10 9 Mo). Toxicities were mild including fever, chills and abdominal pain. There was no treatment-induced thromboembolic event or capillary leak syndrome. The degree of Mo activation in vitro was shown by the release of procoagulant activity and monokines (IL-1, TN Fa and IL-6) in the culture supernatants and the antitumor activity against U937 cells and human ovarian carcinoma cells in vitro and in tumor-bearing nude mice in vivo. The in vivo immunomodulatory activity of i.p. infused Mo was demonstrated by an elevation of WBC and granulocyte counts, fibrinogen, C-reactive protein and neopterin in peripheral blood and generation of IL-1, TFNa and IL-6 in peritoneal fluid. Phase II clinical trials, now in progress, should further define the therapeutic potential of human adoptive cellular immunotherapy using Mo or MØ." @default.
• W2394497789 created "2016-06-24" @default.
• W2394497789 creator A5000022099 @default.
• W2394497789 creator A5015627758 @default.
• W2394497789 creator A5032776602 @default.
• W2394497789 creator A5034324233 @default.
• W2394497789 creator A5035259863 @default.
• W2394497789 creator A5036058817 @default.
• W2394497789 creator A5046527283 @default.
• W2394497789 creator A5051991028 @default.
• W2394497789 creator A5055254464 @default.
• W2394497789 creator A5067570560 @default.
• W2394497789 date "1991-05-01" @default.
• W2394497789 modified "2023-10-14" @default.
• W2394497789 title "Apheresis-Elutriation Program for Adoptive Immunotherapy with Autologous Activated Monocytes in Cancer Patients" @default.
• W2394497789 cites W135854549 @default.
• W2394497789 cites W1815665069 @default.
• W2394497789 cites W190052799 @default.
• W2394497789 cites W1951776719 @default.
• W2394497789 cites W1995225641 @default.
• W2394497789 cites W2075582168 @default.
• W2394497789 cites W2079807385 @default.
• W2394497789 cites W2322553446 @default.
• W2394497789 doi "https://doi.org/10.1177/039139889101400511" @default.
• W2394497789 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1864656" @default.
• W2394497789 hasPublicationYear "1991" @default.
• W2394497789 type Work @default.
• W2394497789 sameAs 2394497789 @default.
• W2394497789 citedByCount "17" @default.
• W2394497789 countsByYear W23944977892016 @default.
• W2394497789 countsByYear W23944977892018 @default.
• W2394497789 countsByYear W23944977892019 @default.
• W2394497789 countsByYear W23944977892020 @default.
• W2394497789 crossrefType "journal-article" @default.
• W2394497789 hasAuthorship W2394497789A5000022099 @default.
• W2394497789 hasAuthorship W2394497789A5015627758 @default.
• W2394497789 hasAuthorship W2394497789A5032776602 @default.
• W2394497789 hasAuthorship W2394497789A5034324233 @default.
• W2394497789 hasAuthorship W2394497789A5035259863 @default.
• W2394497789 hasAuthorship W2394497789A5036058817 @default.
• W2394497789 hasAuthorship W2394497789A5046527283 @default.
• W2394497789 hasAuthorship W2394497789A5051991028 @default.
• W2394497789 hasAuthorship W2394497789A5055254464 @default.
• W2394497789 hasAuthorship W2394497789A5067570560 @default.
• W2394497789 hasConcept C10205521 @default.
• W2394497789 hasConcept C126322002 @default.
• W2394497789 hasConcept C137061746 @default.
• W2394497789 hasConcept C154317977 @default.
• W2394497789 hasConcept C1621761 @default.
• W2394497789 hasConcept C185592680 @default.
• W2394497789 hasConcept C202751555 @default.
• W2394497789 hasConcept C203014093 @default.
• W2394497789 hasConcept C2776738589 @default.
• W2394497789 hasConcept C2777371436 @default.
• W2394497789 hasConcept C2777701055 @default.
• W2394497789 hasConcept C2778594517 @default.
• W2394497789 hasConcept C28328180 @default.
• W2394497789 hasConcept C54355233 @default.
• W2394497789 hasConcept C55493867 @default.
• W2394497789 hasConcept C71924100 @default.
• W2394497789 hasConcept C86803240 @default.
• W2394497789 hasConcept C8891405 @default.
• W2394497789 hasConcept C89560881 @default.
• W2394497789 hasConcept C98274493 @default.
• W2394497789 hasConceptScore W2394497789C10205521 @default.
• W2394497789 hasConceptScore W2394497789C126322002 @default.
• W2394497789 hasConceptScore W2394497789C137061746 @default.
• W2394497789 hasConceptScore W2394497789C154317977 @default.
• W2394497789 hasConceptScore W2394497789C1621761 @default.
• W2394497789 hasConceptScore W2394497789C185592680 @default.
• W2394497789 hasConceptScore W2394497789C202751555 @default.
• W2394497789 hasConceptScore W2394497789C203014093 @default.
• W2394497789 hasConceptScore W2394497789C2776738589 @default.
• W2394497789 hasConceptScore W2394497789C2777371436 @default.
• W2394497789 hasConceptScore W2394497789C2777701055 @default.
• W2394497789 hasConceptScore W2394497789C2778594517 @default.
• W2394497789 hasConceptScore W2394497789C28328180 @default.
• W2394497789 hasConceptScore W2394497789C54355233 @default.
• W2394497789 hasConceptScore W2394497789C55493867 @default.
• W2394497789 hasConceptScore W2394497789C71924100 @default.
• W2394497789 hasConceptScore W2394497789C86803240 @default.
• W2394497789 hasConceptScore W2394497789C8891405 @default.
• W2394497789 hasConceptScore W2394497789C89560881 @default.
• W2394497789 hasConceptScore W2394497789C98274493 @default.
• W2394497789 hasIssue "5" @default.
• W2394497789 hasLocation W23944977891 @default.
• W2394497789 hasLocation W23944977892 @default.
• W2394497789 hasOpenAccess W2394497789 @default.
• W2394497789 hasPrimaryLocation W23944977891 @default.
• W2394497789 hasRelatedWork W1580498340 @default.
• W2394497789 hasRelatedWork W1924286813 @default.
• W2394497789 hasRelatedWork W1985132089 @default.
• W2394497789 hasRelatedWork W2048004943 @default.
• W2394497789 hasRelatedWork W2065938780 @default.
• W2394497789 hasRelatedWork W2098968962 @default.
• W2394497789 hasRelatedWork W2142975690 @default.
• W2394497789 hasRelatedWork W2414550328 @default.
• W2394497789 hasRelatedWork W2892269220 @default.

• next